Breathe Well Live Well
|
Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive …
PR Newswire (press release) Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may … |
View full post on asthma – Google News
|
Asthma Therapeutics in Asia-Pacific Markets to 2021 – Launch of Late-Stage Biologics will Drive the Market in Spite …
Business Wire (press release) Over the 2015-2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion. Analysis of clinical trials since … |
View full post on asthma – Google News
|
Teva's asthma candidates successful in three late-stage studies; regulatory …
Seeking Alpha Top-line results from three Phase 3 clinical trials assessing Teva Pharmaceutical Industries' (TEVA +0.4%) fluticasone propionate/salmeterol, a combination inhaled corticosteroid and long-acting beta agonist delivered via a multidose dry powder inhaler … |
View full post on asthma – Google News
|
In late-stage study, Novartis finds asthma drug effective at reducing itch …
MedCity News ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study. The third and … |
View full post on asthma – Google News
|
Glaxo starting late-stage study of asthma drug
CBS News British drugmaker GlaxoSmithKline PLC said Monday that it is starting two late-stage patient studies of an experimental biologic drug as an add-on treatment for patients with severe, uncontrolled asthma. Both studies will compare the safety and … |
View full post on asthma – Google News
|
Glaxo starting late-stage study of asthma drug
Businessweek British drugmaker GlaxoSmithKline PLC said Monday that it is starting two late-stage patient studies of an experimental biologic drug as an add-on treatment for patients with severe, uncontrolled asthma. Both studies will compare the safety and … GlaxoSmithKline starts final-stage tests on severe asthma drug GSK Begins Phase lll Program for Mepolizumab in Severe Refractory Asthma GSK starts final-stage tests on severe asthma drug |
View full post on asthma – Google News
|
MediciNova Asthma Compound Poised for Late-Stage Trials
San Diego Business Journal By Julie Gallant Tuesday, May 29, 2012 Local biopharmaceutical company MediciNova Inc. received enough positive news from a phase 2b clinical trial evaluating its MN-221 asthma compound to pursue planning for phase 3 trials. |
View full post on asthma – Google News